DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0014247 A1 Kidron (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0014247 A1 Kidron (43) Pub US 2011 0014247A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0014247 A1 Kidron (43) Pub. Date: Jan. 20, 2011 (54) METHODS AND COMPOSITIONS FOR ORAL Related U.S. Application Data ADMINISTRATION OF PROTEINS (60) Provisional application No. 61/064,779, filed on Mar. 26, 2008. (75) Inventor: Miriam Kidron, Jerusalem (IL) Publication Classification (51) Int. Cl. Correspondence Address: A638/16 (2006.01) WOLF GREENFIELD & SACKS, PC. A6IR 9/00 (2006.01) 6OO ATLANTIC AVENUE A638/19 (2006.01) BOSTON, MA 02210-2206 (US) A638/2 (2006.01) A638/43 (2006.01) A638/28 (2006.01) (73) Assignee: ORAMED LTD., Jerusalem (IL) A638/27 (2006.01) A6IP3/10 (2006.01) (21) Appl. No.: 12/934,754 (52) U.S. Cl. ...... 424/400; 424/85.1; 424/85.5; 424/85.7; 424/94.1: 514/1.1 : 514/6.5: 514/6.9; 514/11.3 (22) PCT Fled: Feb. 26, 2009 (57) ABSTRACT This invention provides compositions that include a protein (86) PCT NO.: PCT/IL09/00223 and at least two protease inhibitors, method for treating dia betes mellitus, and methods for administering same, and S371 (c)(1), methods for oral administration of a protein with an enzy (2), (4) Date: Sep. 27, 2010 matic activity, including orally administering same. Patent Application Publication Jan. 20, 2011 Sheet 1 of 3 US 2011/0014247 A1 Figure 1A 8 mg insulin/150 mg EDTA 125 mg SBTI 10 105 100 95 90 85 80 Time (min.) Figure 1B 8 mg insulin/150 mg EDTA/150000 KIU Aprotinin S is S S S eS & KS & S Time (min.) Figure 1C 8 mg insulin/150 mg EDTA/150000 KIU Aprotinin/125 mg SBTI Time (min.) Patent Application Publication Jan. 20, 2011 Sheet 2 of 3 US 2011/0014247 A1 Figure 1D 8 mg insulin/150 mg EDTA/125 mg SBTI 14 is 12 g O E i 4 - 2 - O Time (min.) Figure E 8 mg insulin/150 mg EDTA/150000 KUAprotinin SS O E 5 2 Time (min.) Figure 1F 8 mg insulin/150 mg EDTA/150000 KIU Aprotinin/125 mg SBTI 2O 1 O O Time (min.) Patent Application Publication Jan. 20, 2011 Sheet 3 of 3 US 2011/0014247 A1 Figure 1G 8 mg insulin/150 mg EDTA/125 mg SBTI 2. Time (min.) Figure 1H 8 mg insulin/150 mg EDTA/150000 KIU Aprotinin 2 O Q s Time (min.) Figure 1I 8 mg insulin/150 mg EDTA/150000 KIU Aprotinin/125 mg SBTI SS 2 1.5 3 i 0.5 cs 0 Time (min.) US 2011/0014247 A1 Jan. 20, 2011 METHODS AND COMPOSITIONS FOR ORAL thereof and a first protease inhibitor and a second protease ADMINISTRATION OF PROTEINS inhibitor, thereby treating diabetes mellitus. FIELD OF INVENTION BRIEF DESCRIPTION OF THE DRAWINGS 0010 FIG.1. is a set of bar graphs showing the changes in 0001. This invention provides oral compositions compris blood glucose levels after treatment with the formulations of ing a protein and at least two protease inhibitors and a method the invention. for administering same. 0011. In FIG. 1 A-C blood glucose levels were signifi cantly reduced in human subjects treated with formulation (3) BACKGROUND OF THE INVENTION (8 mg insulin, 150 mg EDTA, 150000 KIU Aprotinin, 125 mg SBTI in 1 ml fish oil in a soft-gel capsule (SwissCup). 0002. Due to improved biotechnology, the accessibility of 0012 FIG. 1D-F shows that total blood insulin was sig biologically active peptides to the pharmaceutical industry nificantly higher especially between 220-300 minutes in has increased considerably. However, a limiting factor in the human subjects treated with formulation (3). development of peptide drugs is the relative ineffectiveness (0013 FIG. 1G-I, shows that blood C-peptide levels were when given perorally. Almost all peptide drugs are parenter significantly reduced in human Subjects treated with formu ally administered, although parenterally administered pep tide drugs are often connected with low patient compliance. lation (3) 0003 Insulin is a medicament used to treat patients suf DETAILED DESCRIPTION OF THE INVENTION fering from diabetes, and is the only treatment for insulin dependent diabetes mellitus. Diabetes Mellitus is character 0014. This invention provides compositions and methods ized by a pathological condition of absolute or relative insulin comprising a protein and at least two protease inhibitors. In deficiency, leading to hyperglycemia, and is one of the main another, embodiment, the present invention provides compo threats to human health in the 21st century. The global figure sitions and methods comprising a protein and a first protease of people with diabetes is set to rise to 220 million in 2010, inhibitor and a second protease inhibitors. In another, and 300 million in 2025. Type I diabetes is caused primarily embodiment, the present invention provides compositions by the failure of the pancreas to produce insulin. Type II and methods comprising a protein having a molecular weight diabetes, involves a lack of responsiveness of the body to the of up to 100,000 Daltons and a first protease inhibitor and a action of insulin. second protease inhibitors. 0004. Approximately 20%-30% of all diabetics use daily 0015. In another, embodiment, the protein of the present insulin injections to maintain their glucose levels. An esti invention has a molecular weight of 1,000-5,000 Daltons. In mated 10% of all diabetics are totally dependent on insulin another, embodiment, the protein of the present invention has injections. a molecular weight of 5,000-10,000 Daltons. In another, 0005. Currently, the only route of insulin administration is embodiment, the protein of the present invention has a injection. Daily injection of insulin is causes considerable molecular weight of 10,000-20,000 Daltons. In another, suffering for patients. Side effects such as lipodystrophy at embodiment, the protein of the present invention has a the site of the injection, lipatrophy, lipohypertrophy, and molecular weight of 20,000-30,000 Daltons. In another, occasional hypoglycemia are known to occur. In addition, embodiment, the protein of the present invention has a Subcutaneous administration of insulin does not typically molecular weight of 40,000-50,000 Daltons. In another, provide the fine continuous regulation of metabolism that embodiment, the protein of the present invention has a occurs normally with insulin secreted from the pancreas molecular weight of 50,000-60,000 Daltons. In another, directly into the liver via the portal vein. embodiment, the protein of the present invention has a molecular weight of 60,000-70,000 Daltons. In another, 0006. The present invention addresses the need for an embodiment, the protein of the present invention has a alternate solution for administration of insulin. molecular weight of 70,000-80,000 Daltons. In another, embodiment, the protein of the present invention has a SUMMARY OF THE INVENTION molecular weight of 80,000-90,000 Daltons. In another, embodiment, the protein of the present invention has a 0007. This invention provides, in one embodiment, a com molecular weight of 90,000-100,000 Daltons. In another, position comprising a protein or a combination of proteins embodiment, the protein of the present invention has a having a molecular weight of up to 100,000 Daltons and a first molecular weight of 100,000-150,000 Daltons. protease inhibitor and a second protease inhibitor. 0016. In another embodiment, the protein has a molecular 0008. In another embodiment, the present invention pro weight (MW) of 1-50 kilodalton (kDa). In another embodi vides a method for oral administration of a protein having a ment, the MW is 1-45 kDa. In another embodiment, the MW molecular weight up to 100,000 Daltons to a subject, whereby is 1-40 kDa. In another embodiment, the MW is 1-35kDa. In a substantial fraction of the protein retains its activity after another embodiment, the MW is 1-30 kDa. In another absorption, through an intestinal mucosalbarrier of a subject, embodiment, the MW is 1-25 kDa. In another embodiment, comprising administering orally to a Subject a pharmaceutical the MW is 1-20 kDa. In another embodiment, the MW is composition comprising the protein and a first protease 10-50 kDa. In another embodiment, the MW is 15-50kDa. In inhibitor and a second protease inhibitor. another embodiment, the MW is 20-50 kDa. In another 0009. In another embodiment, the present invention pro embodiment, the MW is 25-50 kDa. In another embodiment, vides a method for treating diabetes mellitus in a subject, the MW is 30-50 kDa. In another embodiment, the MW is comprising administering orally to a Subject a pharmaceutical 35-50kDa. In another embodiment, the MW is 1-100kDa. In composition comprising insulin, Exenatide, or a combination another embodiment, the MW is 1-90 kDa. In another US 2011/0014247 A1 Jan. 20, 2011 embodiment, the MW is 1-80 kDa. In another embodiment, ment, the amount is 0.1-2 u?kg. In another embodiment, the the MW is 1-70kDa. In another embodiment, the MW is 1-60 amount is 0.2-2 u?kg. In another embodiment, the amount is kDa. In another embodiment, the MW is 10-100 kDa. In 0.3-2 u/kg. In another embodiment, the amount is 0.5-2 u/kg. another embodiment, the MW is 15-100 kDa. In another In another embodiment, the amount is 0.7-2 u/kg. In another embodiment, the MW is 20-100kDa. In another embodiment, embodiment, the amount is 1-2 u?kg. In another embodiment, the MW is 25-100 kDa. In another embodiment, the MW is the amount is 1.2-2 u?kg.
Load more

Recommended publications
  • Acute Phase Proteins and Biomarkers for Health in Chickens Emily
    O'Reilly, Emily (2016) Acute phase proteins and biomarkers for health in chickens. PhD thesis http://theses.gla.ac.uk/7428/ Copyright and moral rights for this thesis are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the Author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the Author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Glasgow Theses Service http://theses.gla.ac.uk/ [email protected] 1 Acute phase proteins and biomarkers for health in chickens Emily Louise O’Reilly B.Sc. (Hon), BVMS, M.Sc. Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy (Ph.D.) Institute of Biodiversity, Animal Health and Comparative Medicine College of Medical, Veterinary and Life Sciences University of Glasgow February 2016 © E. L. O’Reilly, 2016 2 Abstract Acute phase proteins (APPs) are proteins synthesised predominantly in the liver, whose plasma concentrations increase (positive APP) or decrease (negative APP) as a result of infection, inflammation, trauma and tissue injury. They also change as a result of the introduction of immunogens such as bacterial lipopolysaccharide (LPS), turpentine and vaccination. While publications on APPs in chickens are numerous, the limited availability of anti-sera and commercial ELISAs has resulted in a lot of information on only a few APPs.
    [Show full text]
  • Erature and Shear Thinning Behaviour, Suggesting That Ovomucin Can Be Used As a Thickener and Stabilizer in Various Applications
    University of Alberta N-glycosylation and gelling properties of ovomucin from egg white by Marina Offengenden A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Master of Science in Food Science and Technology Department of Agricultural, Food and Nutritional Science ©Marina Offengenden Fall 2011 Edmonton, Alberta Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission. Dedication To Ron, my shining sun on cloudy days Abstract Ovomucin is a bioactive egg white glycoprotein responsible for its gel-like properties and is believed to be involved in egg white thinning, a natural process that occurs during storage. Ovomucin is composed of two subunits: a carbohydrate-rich β-ovomucin and a carbohydrate-poor α-ovomucin. N- glycosylation of ovomucin was studied by nano LC ESI-MS, MS/MS and MALDI MS. Both proteins were N-glycosylated and site-occupancy of 18 potential N-glycosylation sites in α-ovomucin and two sites in β-ovomucin was determined.
    [Show full text]
  • Anticancer and Immunomodulatory Activity of Egg Proteins and Peptides: a Review
    Anticancer and immunomodulatory activity of egg proteins and peptides: a review J. H. Lee and H.-D. Paik1 Department of Food Science and Biotechnology of Animal Resources, Konkuk University, Seoul 05029, Korea ABSTRACT Eggs are widely recognized as a highly mortality worldwide, and therefore research aimed at nutritious food source that offer specific health benefits developing new treatments for cancer immunotherapy for humans. Eggs contain all of the proteins, lipids, vi- is of great interest. The present review focuses primar- tamins, minerals, and growth factors necessary for em- ily on the anticancer and immunomodulatory activities bryonic development. In particular, egg white and yolk of egg proteins and their peptides and provides some proteins are considered functional food substances be- insight into their underlying mechanisms of action. A cause they possess biological activities such as antimi- number of egg proteins and peptides have been reported crobial, antioxidant, metal-chelating, antihypertensive, to induce apoptosis in cancer cells, protect against anticancer, and immunomodulatory activities. Peptides DNA damage, decrease the invasion ability of cancer produced via processes such as enzymatic hydroly- cells, and exhibit cytotoxic and antimutagenic activity sis, fermentation by microorganisms, and some chemi- in various cancer cell lines. Furthermore, egg proteins cal and physical treatments of egg proteins have been and peptides can stimulate or suppress pro- or anti- shown to enhance the functional properties and solu- inflammatory cytokines, as well as affect the production bility of these peptides. Peptide activity is strongly re- of inflammatory mediators in a variety of cell lines. In lated to amino acid sequence, composition, and length.
    [Show full text]
  • Functional Proteins and Peptides of Hen's Egg Origin
    Chapter 5 Functional Proteins and Peptides of Hen’s Egg Origin Adham M. Abdou, Mujo Kim and Kenji Sato Additional information is available at the end of the chapter http://dx.doi.org/10.5772/54003 1. Introduction Hen’s egg has long history as a food. It contains a great variety of nutrients to sustain both life and growth. Egg provides an excellent, inexpensive and low calorie source of high- quality proteins. Moreover, Eggs are a good source of several important nutrients including protein, total fat, monounsaturated fatty acids, polyunsaturated fatty acids, cholesterol, choline, folate, iron, calcium, phosphorus, selenium, zinc and vitamins A, B2, B6, B12, D, E and K [1]. Eggs are also a good source of the antioxidant carotenoids, lutein and zeaxanthin [2]. The high nutritional properties of eggs make them ideal for many people with special dietary requirements. Egg proteins are nutritionally complete with a good balance of essential amino acids which are needed for building and repairing the cells in muscles and other body tissues [3]. Egg proteins are distributed in all parts of the egg, but most of them are present in the egg white and egg yolk amounting to 50% and 40%, respectively. The remaining amount of protein is in the egg shell and egg shell membranes. In addition to excellent nutritional value, egg proteins have unique biological activities. Hyperimmunized hens could provide a convenient and economic source of specific immunoglobulin in their yolks (IgY) that have been found to be effective in preventing many bacteria and viruses infections [4]. Proteins in the egg white as lysozyme, ovotransferrin, and avidin have proven to exert numerous biological activities.
    [Show full text]
  • Isolation and Characterization of Ovomucin – a Bioactive Agent of Egg White
    DOCTORAL THESES IN FOOD SCIENCES AT THE UNIVERSITY OF TURKU /ƐŽůĂƟŽŶĂŶĚ ŚĂƌĂĐƚĞƌŝnjĂƟŽŶŽĨKǀŽŵƵĐŝŶ ͲĂŝŽĂĐƟǀĞŐĞŶƚŽĨŐŐtŚŝƚĞ JAAKKO HIIDENHOVI Food Chemistry and Food Development Department of Biochemistry DOCTORAL THESES IN FOOD SCIENCES AT THE UNIVERSITY OF TURKU Food Chemistry Isolation and Characterization of Ovomucin - a Bioactive Agent of Egg White JAAKKO HIIDENHOVI Food Chemistry and Food Development Department of Biochemistry TURKU, FINLAND – 2015 Food Chemistry and Food Development Department of Biochemistry University of Turku, Finland Supervised by Director Eeva-Liisa Ryhänen, Ph.D. Green Technology Natural Resources Institute Finland (Luke) Jokioinen, Finland Professor Rainer Huopalahti, Ph.D. Department of Biochemistry University of Turku Turku, Finland Reviewed by Professor Francoise Nau, Ph.D. Agrocampus Ouest UMR1253 Dairy and Egg Science and Technology Rennes, France Professor Olli Lassila, MD, Ph.D. Department of Biomedicine University of Turku Turku, Finland Opponent Professor Markku Kulomaa, Ph.D. BMT / Molecular Biotechnology University of Tampere Tampere, Finland Research director Professor Heikki Kallio, Ph.D. Department of Biochemistry University of Turku Turku, Finland The originality of this dissertation has been checked in accordance with the University of Turku quality assurance system using the Turnitin OriginalityCheck service ISBN 978-951-29-6114-6 (print) ISBN 978-951-29-6115-3 (pdf) ISSN 2323-9395 (print) ISSN 2323-9409 (pdf) Painosalama Oy – Turku, Finland 2015 In memory of my parents Table of Contents TABLE
    [Show full text]
  • Eggshell Membrane Proteins Provide Innate Immune Protection
    Eggshell Membrane Proteins provide Innate Immune Protection Cristianne Martins Monteiro Cordeiro This Thesis is submitted to the Faculty of Graduate and Postdoctoral Studies in partial fulfillment of the requirements for the Doctorate in Philosophy degree in Cellular and Molecular Medicine Department of Cellular and Molecular Medicine Faculty of Medicine University of Ottawa Cristianne Martins Monteiro Cordeiro, Ottawa, Canada, 2015 Abstract The microbiological safety of avian eggs is a major concern for the poultry industry and for consumers due to the potential for severe impacts on public health. Innate immune defense is formed by proteins with antimicrobial and immune-modulatory activities and ensures the protection of the chick embryo against pathogens. The objective of this project was to identify the chicken eggshell membrane (ESM) proteins that play a role in these innate immune defense mechanisms. We hypothesized that ESM Ovocalyxin-36 (OCX-36) is a pattern recognition protein, and characterized purified ESM OCX-36. OCX-36 has antimicrobial activity against S. aureus and binds E. coli lipopolysaccharide (LPS) and S. aureus lipoteichoic acid (LTA). We additionally investigated the OCX-36 nonsynonymous single nucleotide polymorphisms (SNPs) at cDNA position 211. The corresponding isoforms (proline-71 or serine-71) were purified from eggs collected from genotyped homozygous hens. A significant difference between Pro- 71 and Ser-71 OCX-36s for S. aureus LTA binding activity was observed. From these experiments, we confirmed the hypothesis that OCX-36 is a pattern recognition molecule. We also found that OCX-36 has anti-endotoxin properties and is a macrophage immunostimulator to produce NO and TNF-α.
    [Show full text]
  • Supporting Information for Proteomics DOI 10.1002/Pmic.200500648
    Supporting Information for Proteomics DOI 10.1002/pmic.200500648 Fiona M. McCarthy, Amanda M. Cooksey, Nan Wang, Susan M. Bridges, G. Todd Pharr and Shane C. Burgess Modeling a whole organ using proteomics: The avian bursa of Fabricius ª 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com Supporting Text: Determining Tissue Expression Patterns for Transcription Factors. We identified 107 transcription factors (TFs) from post-hatch bursas. Since the Transfac database (1) did not contain all of these TFs, we used PubMed literature searches to determine expression patterns for each. For each transcription factor, we searched PubMed for a combination of the protein and gene names, as determined by both NCBI and UniProt records. For example, Pax7 (gi:2576239; UniProt O42349) was searched as both PAX7 and Pax-7. In each case, articles were manually searched to confirm TF expression. We combined the TF names with the following terms to obtain reported tissue expression patterns: 1. Expression in the bursa. AND bursa* OR DT40 eg. (Pax7 OR “Pax-7”) AND (bursa* OR DT40) returned no items. 2. Expression in immune tissue. AND lymphocyte* OR leukocyte* OR “bone marrow” OR spleen OR “embryonic liver” OR hematopoietic eg. (Pax7 OR “Pax-7”) AND (lymphocyte* OR leukocyte* OR “bone marrow” OR spleen OR “embryonic liver” OR hematopoietic) returned 17 articles. 3. Expression during development. AND development OR embryo* eg. (Pax7 OR “Pax-7”) AND (development OR embryo*) returned 135 articles. 4. Expression in nervous tissue. AND neuron* OR nervous OR CNS OR retina* 1 eg. (Pax7 OR “Pax-7”) AND (neuron* OR nervous OR CNS OR retina*) returned 53 articles.
    [Show full text]
  • WO 2016/077457 Al 19 May 2016 (19.05.2016) P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/077457 Al 19 May 2016 (19.05.2016) P O PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A23J3/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 15/060 147 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 11 November 2015 ( 11. 1 1.2015) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/078,385 11 November 2014 ( 11. 11.2014) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: CLARA FOODS CO. [US/US]; 2325 3rd TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Street, Suite 202, San Francisco, CA 94107 (US).
    [Show full text]
  • The Role of Ovotransferrin in Egg-White Antimicrobial Activity: a Review
    foods Review The Role of Ovotransferrin in Egg-White Antimicrobial Activity: A Review Julie Legros 1,2 , Sophie Jan 1 , Sylvie Bonnassie 3, Michel Gautier 1, Thomas Croguennec 1 , Stéphane Pezennec 1 , Marie-Françoise Cochet 1 , Françoise Nau 1 , Simon C. Andrews 2 and Florence Baron 1,* 1 STLO, INRAE, Institut Agro, 35042 Rennes, France; [email protected] (J.L.); [email protected] (S.J.); [email protected] (M.G.); [email protected] (T.C.); [email protected] (S.P.); [email protected] (M.-F.C.); [email protected] (F.N.) 2 School of Biological Sciences, Health and Life Sciences Building, University of Reading, Reading RG6 6AX, UK; [email protected] 3 UFR Sciences de la vie et de L’environnement, Université de Rennes 1, 35000 Rennes, France; [email protected] * Correspondence: fl[email protected] Abstract: Eggs are a whole food which affordably support human nutritional requirements world- wide. Eggs strongly resist bacterial infection due to an arsenal of defensive systems, many of which reside in the egg white. However, despite improved control of egg production and distribution, eggs remain a vehicle for foodborne transmission of Salmonella enterica serovar Enteritidis, which continues to represent a major public health challenge. It is generally accepted that iron deficiency, Citation: Legros, J.; Jan, S.; mediated by the iron-chelating properties of the egg-white protein ovotransferrin, has a key role Bonnassie, S.; Gautier, M.; in inhibiting infection of eggs by Salmonella. Ovotransferrin has an additional antibacterial activity Croguennec, T.; Pezennec, S.; Cochet, beyond iron-chelation, which appears to depend on direct interaction with the bacterial cell surface, M.-F.; Nau, F.; Andrews, S.C.; Baron, resulting in membrane perturbation.
    [Show full text]
  • ― D12 - 1 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版（ 2019） カテゴリー別リスト
    医学中央雑誌刊行会・医学用語シソーラス 第9版（ 2019） カテゴリー別リスト Amino Acids, Peptides, and Proteins D12+ Amino Acids D12-10+ Acidic Amino Acids D12-10-10+ Aspartic Acid D12-10-10-10+ # D-Aspartic Acid D12-10-10-10-10 # * Calcium Aspartate D12-10-10-10-20 # Isoaspartic Acid D12-10-10-10-30 # N-Methylaspartate D12-10-10-10-40 # * Potassium Aspartate D12-10-10-10-50 # Potassium Magnesium Aspartate D12-10-10-10-60 # Sparfosic Acid D12-10-10-10-70 # Glutamates D12-10-10-20+ # 1-Carboxyglutamic Acid D12-10-10-20-10 # * Carglumic Acid D12-10-10-20-20 # Glutamic Acid D12-10-10-20-30+ # Sodium Glutamate D12-10-10-20-30-10 # Pemetrexed D12-10-10-20-40 # Polyglutamic Acid D12-10-10-20-50+ # Paclitaxel Poliglumex D12-10-10-20-50-10 # Pyrrolidonecarboxylic Acid D12-10-10-20-60 # Alanine D12-10-20+ Alafosfalin D12-10-20-10 # Alanosine D12-10-20-20 # Alaproclate D12-10-20-30 # Beta-Alanine D12-10-20-40+ Pantothenic Acid D12-10-20-40-10+ # Hopantenic Acid D12-10-20-40-10-10 # Panthenol D12-10-20-40-10-20 # Betamipron D12-10-20-50 Brivanib Alaninate D12-10-20-60 # Lysinoalanine D12-10-20-70 # Managlinat Dialanetil D12-10-20-80 # Mimosine D12-10-20-90 # Orbofiban D12-10-20-100 # Rebamipide D12-10-20-110 # Safinamide D12-10-20-120 # Semagacestat D12-10-20-130 # Amino Acid Chloromethyl Ketones D12-10-30+ # Tosyllysine Chloromethyl Ketone D12-10-30-10 # Tosylphenylalanyl Chloromethyl Ketone D12-10-30-20 # Amino Acyl tRNA D12-10-40 # Aminobutyrates D12-10-50+ # Aminoisobutyric Acids D12-10-50-10 # Gamma-Aminobutyric Acid D12-10-50-20+ # Carpronium Chloride D12-10-50-20-10 # Gabapentin
    [Show full text]
  • Amigos. 2002-03 Batch. TNPSC Notes. Animal & Vet Science Refresher
    AMIGOS 2002-03 BATCH TNPSC NOTES I. PHYSIOLOGY LOCOMOTION • PM Contraction - Rigor Mortis • PM Cooling - Algor Mortis • PM Staining - Livor Mortis • Creatine phosphate in muscle is referred to as ATP sparer or energy buffer • Each molecule of glucose produce – 38 ATPs • About 5-6 hrs after death, all muscles of the body assume a state of contracture – Rigor Mortis • The efficiency of muscle contraction is – 45% • Muscle contraction without shortening in length – Isometric Contraction • Whole cardiac muscle obeys all or none law because of Syncytium • Refractory period is the brief period during which muscles undergoing contraction for a first stimuli is unable to respond to a second stimuli • The energy of contraction of muscle is directly proportional to the length of the fibre- Sterling law • Tetanisation is the fusion of successive twitches when the frequency of stimuli is given at a rapid rate • Myasthenia gravis is a neuromuscular disorder in which auto antibodies are produced against Ach receptors BLOOD • Plasma constitutes about 55-70% of blood • Viscosity in blood is provided by gamma globulins • Arterial blood is more Alkaline than venous blood • Yellow colour of the plasma is due to Bilirubin Page | 1 AMIGOS 2002-03 BATCH TNPSC NOTES • Serum differs from plasma lacking fibrinogen, prothrombin and other coagulation factors • RBC of species o Biconcave - Dog, Cow, Sheep o Shallow/flat - Goat o Shallow concave - Horse, Cat o Elliptical, sickle shape - Camel , Deer o Elliptical & nucleated - Birds, Amphibians • Poikilocytosis
    [Show full text]
  • Proteomic Analysis of Fertilized Egg White During Early Incubation
    e u pa open proteomics 2 (2014) 38–59 Available online at www.sciencedirect.com ScienceDirect journal homepage: http://www.elsevier.com/locate/euprot Proteomic analysis of fertilized egg white during early incubation Jiapei Wang, Jianping Wu ∗ Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada T6G 2P5 article info abstract Article history: Proteomic analysis of egg white proteins was performed to elucidate their metabolic fates Received 23 September 2013 during first days of embryo development using 2-DE coupled with a LC–MS/MS. A total of Received in revised form 91 protein spots were analyzed, representing 37 proteins belonging to ‘Gallus gallus’, of 19 29 October 2013 proteins were detected in egg whites for the first time, such as lipoproteins, vitellogenin Accepted 4 November 2013 and zona pellucida C protein. All ovomucoid spots with one exception were significantly (P < 0.05) increased. Marker protein and one flavoprotein spot were significantly increased Keywords: while hemopexin, serum albumin precursor, Ex-FABP precursor and Galline Ex-FABP were Fertilized egg whites significantly decreased. 2-DE © 2013 The Authors. Published by Elsevier B.V. on behalf of European Proteomics Proteomics Association (EuPA). Open access under CC BY-NC-ND license. Incubation Quantification Embryo permeability-increasing protein family (BPI), and VMO-1, an 1. Introduction outer layer vitelline membrane protein, were found for the first time [8]. Mann detected 78 egg white proteins, out of 54 Egg white provides not only many essential nutrients sup- new proteins, using 1-DE and LC–MS/MS [9]. D’Ambrosio et al.
    [Show full text]